Kampanjeplan AusCann Group Holdings Ltd
Avansert tidsplan
Enkel graf
Om selskapet AusCann Group Holdings Ltd
AusCann Group Holdings Ltd engages in the development and commercialization of cannabinoid-derived therapeutic products for humans and animals in Australia and internationally. Its principal product includes the novel tetrahydrocannabinol and cannabidiol (THC/CBD), a powder-based hard-shell capsules based on AusCann's Neuvis platform for the treatment of pain and related indications. The company is also involved in the research and development of medicinal cannabis. It offers its products to healthcare professionals and veterinarians. flere detaljer| Industry | Pharmaceuticals |
|---|---|
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://auscann.com.au |
| Цена ао | 0.0038 |
| Prisendring per dag: | 0% (0.0038) |
|---|---|
| Prisendring per uke: | 0% (0.0038) |
| Prisendring per måned: | 0% (0.0038) |
| Prisendring over 3 måneder: | 0% (0.0038) |
| Prisendring over seks måneder: | -68.33% (0.012) |
| Prisendring per år: | +90% (0.002) |
| Prisendring over 3 år: | -94.63% (0.0708) |
| Prisendring over 5 år: | -97.74% (0.168) |
| Prisendring over 10 år: | 0% (0.0038) |
| Prisendring siden begynnelsen av året: | 0% (0.0038) |
|
|
Undervurdering
|
Effektivitet
|
|||||||||||||||||||||||||||||||||||||
Utbytte
|
Plikt
|
Vekstimpuls
|
|||||||||||||||||||||||||||||||||||||
| Veileder | Stillingstittel | Betaling | Fødselsår |
|---|---|---|---|
| Mr. Christopher Mews A.C.I.S., B. Bus, C.P.A. | Chief Financial Officer | ||
| Ms. Rachel Jelleff Kerr | Company Secretary |
Adresse: Australia, West Perth, 1202 Hay Street - åpne i Google maps, åpne Yandex-kart
Nettsted: https://auscann.com.au
Nettsted: https://auscann.com.au
